Skip to content

英诺维瓦

US · INVA #2990 按市值排名 上市于 1970
20.78 -0.08 -0.38%
实时 - 追踪5344个代码 - 心跳于326秒前 · 2026-10-16 20:02

估值 各估值倍数与自身5年区间的对比

市净率 1.22 低于历史水平 第3百分位
5年平均 1.82 · 在Biotechnology中排名第145/514
市盈率 4.83 低于历史水平 第21百分位
5年平均 10.32 · 前瞻 10.34 · 在Biotechnology中排名第25/73
市销率 3.42 高于历史水平 第68百分位
5年平均 3.18 · 前瞻 3.21 · 在Biotechnology中排名第77/388

同业对比 Biotechnology

公司 市值 市盈率(TTM) 市净率 股息率
英诺维瓦 (INVA) 1.50B 4.82 1.22 0.00%
Vertex Pharmaceuticals (VRTX) 126.66B 29.11 6.26 0.00%
Moderna (MRNA) 87.04B -27.32 12.87 0.00%
Regeneron Pharmaceuticals (REGN) 81.41B 19.57 2.57 0.46%
argenx SE (ARGX) 51.51B 31.21 6.12 0.00%
BeiGene (ONC) 41.96B 65.32 8.11 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★☆☆ 合理价值23.09 经济护城河None 不确定性High

当前股价低于晨星合理价值估算11.1%。

合理价值

Innoviva Inc earns a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 10% discount to our quantitative fair value estimate of $23.09 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's profitability bolsters our valuation estimate. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. Reflecting the firm's profitability is its earnings yield of 9.4%, which falls in the top 30% compared with peers globally. This suggests that it is generating substantial earnings relative to its share price, which contributes to our view that shares are cheap.

Alternatively, the company's unfavorable dividend structure is potentially concerning. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. The firm's forward dividend yield of 0%, for example, ranks in the bottom 30% globally. This could imply a planned dividend cut or relatively high share price, which, despite our favorable price/fair value ratio, is a negative attribute.

经济护城河

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. However, its financial health score is strong, suggesting that the company should be well positioned to weather tough times.

作者:Quantitative Equity Report

报价时间 2026-10-16 20:02:15 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

英诺维瓦 讨论区 0 条评论

发表评论